Dataset from A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Prucalopride in Male Subjects With Chronic Constipation

This is a multi-centre, randomised, parallel-group, double-blind, placebo-controlled phase
III trial to evaluate the efficacy of prucalopride versus placebo over 12 weeks of treatment
in male subjects with chronic constipation.

Furthermore the safety, tolerability, effect on quality of life and effect on symptoms of
prucalopride will be assessed.